Immuno-Oncology beyond TILs: Unleashing TILCs
Authors:
- 1 April 2020
- journal article
- editorial
- Published by Elsevier in Cancer Cell
- Vol. 37 (4) , 428-430
Abstract
No abstract availableKeywords
Funding Information
- Institut National de la Santé et de la Recherche Médicale
- Aix-Marseille Université
- Centre National de la Recherche Scientifique
- Horizon 2020 Framework Programme
- Horizon 2020
- MSDAVENIR
- Agence Nationale de la Recherche (ANR-17-RHUS-0007)
- European Research Council
This publication has 10 references indexed in Scilit:
- Plasticity of innate lymphoid cell subsetsNature Reviews Immunology, 2020
- ILC2s amplify PD-1 blockade by activating tissue-specific cancer immunityNature, 2020
- Innate Lymphoid Cells: 10 Years OnCell, 2018
- Type 2 Innate Lymphocytes Actuate Immunity Against Tumours and Limit Cancer MetastasisScientific Reports, 2018
- Tumour-derived PGD2 and NKp30-B7H6 engagement drives an immunosuppressive ILC2-MDSC axisNature Communications, 2017
- Innate lymphoid cells: major players in inflammatory diseasesNature Reviews Immunology, 2017
- Resolution of inflammation by interleukin-9-producing type 2 innate lymphoid cellsNature Medicine, 2017
- PD-1 regulates KLRG1+ group 2 innate lymphoid cellsJournal of Experimental Medicine, 2017
- Single-cell RNA-seq identifies a PD-1hi ILC progenitor and defines its development pathwayNature, 2016
- Identification of Innate IL-5–Producing Cells and Their Role in Lung Eosinophil Regulation and Antitumor ImmunityThe Journal of Immunology, 2012